CVS Health Co. (NYSE:CVS - Free Report) - Leerink Partnrs lowered their Q4 2024 earnings per share estimates for CVS Health in a research report issued on Wednesday, May 1st. Leerink Partnrs analyst M. Cherny now forecasts that the pharmacy operator will post earnings of $1.94 per share for the quarter, down from their previous estimate of $2.15. Leerink Partnrs has a "Market Perform" rating on the stock. The consensus estimate for CVS Health's current full-year earnings is $7.00 per share. Leerink Partnrs also issued estimates for CVS Health's FY2027 earnings at $9.68 EPS.
CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 EPS for the quarter, missing analysts' consensus estimates of $1.69 by ($0.38). CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The business had revenue of $88.44 billion for the quarter, compared to the consensus estimate of $89.33 billion. During the same period in the prior year, the business earned $2.20 earnings per share. CVS Health's revenue was up 3.7% compared to the same quarter last year.
CVS has been the subject of several other research reports. Wells Fargo & Company reduced their price target on shares of CVS Health from $83.00 to $76.00 and set an "equal weight" rating for the company in a report on Monday, April 8th. Barclays cut their target price on CVS Health from $78.00 to $63.00 and set an "equal weight" rating on the stock in a research report on Thursday. Piper Sandler boosted their price target on CVS Health from $93.00 to $94.00 and gave the company an "overweight" rating in a research note on Friday, March 15th. Truist Financial reaffirmed a "buy" rating and set a $66.00 target price (down previously from $90.00) on shares of CVS Health in a report on Thursday. Finally, Bank of America cut their price target on shares of CVS Health from $95.00 to $77.00 and set a "buy" rating on the stock in a report on Thursday. Eight research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to data from MarketBeat.com, CVS Health presently has a consensus rating of "Moderate Buy" and an average price target of $80.35.
Check Out Our Latest Report on CVS Health
CVS Health Price Performance
Shares of CVS traded up $0.75 during mid-day trading on Friday, hitting $55.90. 23,942,078 shares of the stock were exchanged, compared to its average volume of 11,752,378. The company has a market cap of $70.45 billion, a PE ratio of 9.82, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56. CVS Health has a 52-week low of $53.70 and a 52-week high of $83.25. The firm has a 50-day moving average of $73.19 and a two-hundred day moving average of $73.37. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.63 and a current ratio of 0.81.
CVS Health Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd were issued a dividend of $0.665 per share. The ex-dividend date was Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a yield of 4.76%. CVS Health's payout ratio is currently 46.75%.
Insider Transactions at CVS Health
In related news, Director Edward J. Ludwig purchased 1,000 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were purchased at an average price of $53.88 per share, with a total value of $53,880.00. Following the completion of the acquisition, the director now directly owns 21,630 shares in the company, valued at approximately $1,165,424.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Edward J. Ludwig acquired 1,000 shares of CVS Health stock in a transaction that occurred on Thursday, May 2nd. The stock was purchased at an average cost of $53.88 per share, with a total value of $53,880.00. Following the completion of the acquisition, the director now owns 21,630 shares in the company, valued at approximately $1,165,424.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Prem S. Shah sold 29,473 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the completion of the sale, the executive vice president now directly owns 39,765 shares in the company, valued at approximately $3,059,916.75. The disclosure for this sale can be found here. Insiders own 0.24% of the company's stock.
Hedge Funds Weigh In On CVS Health
A number of institutional investors have recently modified their holdings of the company. Mission Wealth Management LP increased its stake in CVS Health by 4.3% during the third quarter. Mission Wealth Management LP now owns 5,081 shares of the pharmacy operator's stock worth $355,000 after acquiring an additional 210 shares during the last quarter. Stratos Wealth Partners LTD. raised its holdings in CVS Health by 6.2% in the third quarter. Stratos Wealth Partners LTD. now owns 65,885 shares of the pharmacy operator's stock valued at $4,600,000 after buying an additional 3,874 shares during the period. Stratos Wealth Advisors LLC lifted its position in CVS Health by 82.5% during the third quarter. Stratos Wealth Advisors LLC now owns 6,614 shares of the pharmacy operator's stock valued at $462,000 after buying an additional 2,990 shares in the last quarter. NorthRock Partners LLC increased its holdings in CVS Health by 24.0% in the 3rd quarter. NorthRock Partners LLC now owns 8,307 shares of the pharmacy operator's stock valued at $580,000 after purchasing an additional 1,606 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in CVS Health by 2.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 10,678,078 shares of the pharmacy operator's stock worth $745,543,000 after acquiring an additional 266,650 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.
CVS Health Company Profile
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Stories
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
